{"nctId":"NCT00357734","briefTitle":"Iressa Follow-up Trial","startDateStruct":{"date":"2005-01"},"conditions":["Lung Cancer","Breast Cancer"],"count":14,"armGroups":[{"label":"Gefitinib (ZD1839)","type":"EXPERIMENTAL","interventionNames":["Drug: Gefitinib"]}],"interventions":[{"name":"Gefitinib","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of written informed consent to participate in the trial.\n* Female or male aged 18 years and over.\n* Patients with previously diagnosed cancer who have been treated with ZD1839 in a parent ZD1839 clinical trial and may benefit from continuation\n\nExclusion Criteria:\n\n* Known severe hypersensitivity to ZD1839\n* Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.\n* Withdrawal from a parent ZD1839 trial because of tumor progress","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Objective disease progressing was assessed using the previous cancer response criteria in the parent ZD1839 trial: ie Southwest Oncology Group (SWOG) tumor response criteria, as a 50% increase or an increase of 10 cm2 (whichever is smaller) in the sum of products of all measurable lesions from the overall smallest sum observed (over baseline if no decrease) using the same techniques as baseline; Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase In the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Serious Adverse Events (SAEs)","description":"Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Serious Adverse Events (SAEs) Related to ZD1839","description":"Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Other Adverse Events (AEs)","description":"Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Other Adverse Events (AEs) Related to ZD1839","description":"Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":14},"commonTop":["NAUSEA","VOMITING","DIARRHOEA","PNEUMONITIS","DIZZINESS"]}}}